SiteOne Raises $100m For Peripheral Nervous System-Targeting Drugs In Pain And More
Lead Asset Competes With Vertex’s NaV1.8 Inhibitor
SiteOne will use its series C venture capital to complete Phase I and initiate Phase II studies for its NaV1.8 inhibitor STC-004 in acute and chronic pain, and to advance other early programs.
